IL17A and esophageal squamous cell carcinoma: On the one hand, in the ESCC TME, IL-17 can recruit beneficial neutrophils, CD8+ T lymphocytes and B lymphocytes to inhibit tumor growth (Chen et al., 2017; Lu et al., 2016).